News | February 15, 2025
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Subscribe To Our Newsletter & Stay Updated
